Encapso is anticipated to support gross margins in excess of 50%. Solazyme's "Oil Field Services" segment supports the company's second largest target margins. To date, Encapso is the only commercialized product within this market division. Only the "Skin & Personal Care" business division is expected to be more profitable for Solazyme with anticipated gross margins reaching higher than 60%.
Tried to include a link with the period taken out and writing in the word DOT so you could get to the link that showed the slide from the presentation that they and Goldman Sachs gave on the fund raising tour. It shows a slide from SZYM that shows the margins for Industrials and Fuels 30%, Nutrition 40%, Oil Field services 50%, and Skin and Personal Care 60%.
Google search "Kevin Quon 5 Things To Know About Solazyme's Encapso" or look for it under news for Solazyme. Second point contains a blue link listed as ""second largest target margins". Click on it and it will take you to the slide.
My point is...SZYM has made a confirmation on that %. The rest you will have to wait on.